Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Company Logo

Algernon’s business model is based on drug re-purposing, finding new uses for know drugs





 

Stock Quote Today & Recent News Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals is a clinical stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough. The company's business model is highly capital efficient and strives to deliver maximum shareholder value. Algernon's unique approach to drug discovery is based on the concept of drug repurposing.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

"While there are many companies that are working in or attempting to enter the psychedelic drug space, many are a considerable distance from human studies, we announced that we plan to be the first company globally to investigate DMT for stroke and that is a goal that we are getting closer to achieving."

Christopher J. Moreau, CEO

Current News (CSE:AGN)

Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD

GlobeNewswire 4 days ago

Pharmaceutical microcap penny stock is up big after asset sale

Trevor Abes  12 days ago

Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

GlobeNewswire 12 days ago

Algernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast

GlobeNewswire November 8, 2023

Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH

GlobeNewswire September 6, 2023

Algernon to begin Phase 2 psychedelic drug DMT stroke study

Jon Brown August 8, 2023
View More News ››

"Ifenprodil’s anti-tumour effect in this study is very impressive when you consider it does not appear to have the serious side effects typically seen with other chemotherapy agents.Our business plan is to have upwards of three to four Phase 2 trials underway in 2022 and we are very pleased to be adding Ifenprodil with a cancer indication to our pipeline.."

Christopher J. Moreau, CEO

Opinion & Analysis (CSE:AGN)

Biopharma Co. Makes Major Headway Toward Clinical Trials for Treatment of Stroke

Dave Jackson June 16, 2021

Flying Under the Radar with a Possible COVID-19 Treatment

Stockhouse Editorial September 9, 2020

Small-Cap Pharma Fast-Tracking Repurposed Drug for Covid-19

Streetwise Reports May 29, 2020

Buzz on the Bullboards: Coronavirus, Esports, and Uranium Plays

Omri Wallach April 16, 2020

Buzz on the Bullboards: HOT Coronavirus Healthcare Stocks

Omri Wallach March 19, 2020
View More Opinion ››

"We are very pleased to be expanding our Ifenprodil cancer research program to include SCLC,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals. “We also welcome Dr. William North to help us lead the investigation of Ifenprodil’s potential as a new non-toxic cancer therapy."

Christopher J. Moreau, CEO

Bullboard Posts (CSE:AGN)

Today’s Trading

The trend is now well established.  Integral is nowhere on the CSE Depth Display and the mini trades, $75 to $150, all involvie...
nodaytrader - 5 hours ago

Today’s Trading

Down from 9 cents to 7.5 cents today with a total 12 trades so far. All mini trades - the largest being $300 - and all involving National...
nodaytrader - 6 days ago

Trading Update

Price now down to 8 cents. 10 trades so far today. First 5 involve National Bank followed by 5 involving Desjardins.    
nodaytrader - 7 days ago

Todo Trading

Great news from Algernon last week and today, suddenly, we have four trades only, all involving National Bank,that drop the price by a...
nodaytrader - 7 days ago

Microcap penny stock up big on asset sale

https://stockhouse.com/news/the-market-herald-news/2023/11/22/microcap-penny-stock-up-big-on-asset-sale
TrevorAbes - 12 days ago

Algernon announces acquisition of chronic cough program

So what's the real story here? Program acquired by US based Seylyx Inc. they have a barebone website and the domain was registered...
Whalewatcher1 - 12 days ago
View more Bullboard ››

Connect with C.AGN


PIPELINE TARGETED DISEASES MEDIA MANAGEMENT

CEO Clips: DMT Clinical Trial

CEO Q&A Interview with Chris Moreau

Investor Presentation

Download the latest Investor Presentaion

Algernon Highlights: The Watchlist

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Investment Opportunity

The Algernon Value Proposition



  • Advancing new drug treatments for billion dollar global disease markets.
  • Re-purposed compounds have a much lower risk of failing in human trials as a result of safety issues.
  • Conducting multiple phase II clinical trials.
  • Highly capital efficient business model.
  • Experienced management team & globally recognized medical advisory board.

Download the Presentaion

Facebook

Contact Us